[{"id":"bd30c023-8987-4b8d-8c2c-7885f1613d76","acronym":"","url":"https://clinicaltrials.gov/study/NCT04873180","created_at":"2021-05-05T11:52:34.984Z","updated_at":"2024-07-02T16:36:30.581Z","phase":"","brief_title":"Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma","source_id_and_acronym":"NCT04873180","lead_sponsor":"Sohag University","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression • BIRC5 overexpression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression • BIRC5 overexpression"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2021-05-07"},{"id":"d5c302f6-f239-4bba-903a-aaad67b7c5f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00129376","created_at":"2021-01-18T00:26:20.714Z","updated_at":"2024-07-02T16:36:58.407Z","phase":"Phase 2","brief_title":"Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients","source_id_and_acronym":"NCT00129376","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression • BIRC5 overexpression • CDKN1B expression • TOP2A expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression • BIRC5 overexpression • CDKN1B expression • TOP2A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 02/01/2003","start_date":" 02/01/2003","primary_txt":" Primary completion: 07/01/2005","primary_completion_date":" 07/01/2005","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2019-07-05"}]